

Gambro Healthcare, Inc., Receives Subpoena in the US

Stockholm, Sweden, June 20, 2001 – Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that its wholly owned US subsidiary, Gambro Healthcare, Inc., received on June 18, 2001 a subpoena from the United States Department of Justice requesting information concerning Gambro Healthcare, Inc.'s, business activities and operations as part of an investigation by the US Attorney's office in St. Louis, Missouri. Gambro Healthcare, Inc., intends to respond appropriately to the request for information as required by the Department of Justice. Gambro has no further information concerning this matter at this time.

For further information please contact:

Bengt Modéer, Investor Relations, tel. +46-8-613-6533, +46-70-513-6533

Karin Avasalu, Corporate Communications, tel. +46-8-613-6500, +46-70-513-6599

Kevin Smith, Investor Relations US, tel. +1-303-231-4750

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 49,000 patients in 650 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 22 billion (USD 2.4 billion), has approximately 18,500 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Jakobsgatan 6, PO Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com